Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

In this patient group, adjuvant BPs produced highly significant reductions in bone recurrence (RR 0.72, 95% CI 0.60–0.86; 2p=0.0002) and breast cancer mortality (RR 0.82, 0.73–0.93; 2p=0.002).These effects were independent of tumor parameters (estrogen receptor status or grade), nodal status, bisphosphonate class, or dosing schedule or concomitant chemotherapy [ 23 , 26 ].

also in 132,142 other papers